Pyrroloquinoline quinone (PQQ) (2017) & Alzheimer's

In Alzheimer's models Pyrroloquinoline quinone (PQQ) has been found to prevent mitochondrial dysfunction. In a mouse model of AD, a nutraceutical containing PQQ clearly improved motor dysfunction and cognitive impairment, protected mitochondrial function, reduced free radicals, and reduced membrane hyperpolarization. It slightly reduced soluble amyloid beta 42 levels which resulted in reduced tau levels.¹

In other research, with rat models of Alzheimer's, supplementation with PQQ prevented cognitive impairment and partially reversed bioenergy deficits. The researchers described PQQ as "a mitochondrial biogenesis stimulator with antioxidant and neuroprotective effects."²

Research

1. Sawmiller D, Li S, Mori T, Habib A, Rongo D, et al. (2017). Beneficial effects of a pyrroloquinoline quinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer's disease. Heliyon. Apr 4;3(4):e00279.
2. Adami PVM, Quijano C, Magnani N, Galeano P, Evelson P, et al. (2017). Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. J Cereb Blood Flow Metab. Jan;37(1):69-84.